天风证券晨会集萃-20250616

Group 1 - The report highlights a decline in the AH premium from 144.6 in January 2025 to 128 in June 2025, primarily due to the performance of old economy sectors in Hong Kong outperforming their A-share counterparts [3][38] - It suggests that the decline in AH premium is not due to unique assets in Hong Kong but rather the performance of traditional sectors like resources and finance, which have seen higher increases in Hong Kong [36][38] - The report indicates that the core assets in A-shares have shown relative weakness, while companies like Ningde Times, BYD, and China Merchants Bank have exhibited premiums in Hong Kong compared to A-shares [3][38] Group 2 - The macroeconomic environment shows a recovery in manufacturing, with the PMI rising in May, although it remains in a contraction zone [4] - Social financing increased by 2.29 trillion yuan in May, which is 227.1 billion yuan more than the same period last year, indicating a mixed structure in financing sources [4] - The report notes that the recent interest rate cuts and reserve requirement ratio reductions have led to a rebound in M1, while M2 has decreased, reflecting a tightening of excess liquidity [4] Group 3 - The report emphasizes the importance of innovation in the pharmaceutical sector, particularly with the upcoming adjustments to the basic medical insurance and commercial insurance directories, which are expected to favor innovative drugs [10][22] - It highlights that the recent meeting by the State Council regarding drug procurement policies marks a significant step towards optimizing the procurement process, which could positively impact the revenue and profits of generic drug companies [10][22] - The report recommends focusing on innovative drugs as a core investment strategy, given the expected policy support and market potential [10][22] Group 4 - The report discusses the performance of the stock market, noting that the Shanghai Composite Index closed at 3377, down 0.75%, while the Hang Seng Index closed at 23892.56, down 0.59% [8][15] - It indicates that the market is currently in a volatile phase, with a neutral position recommended for investors due to increased macroeconomic uncertainties [6][10] - The report suggests that sectors such as innovative pharmaceuticals, new consumption, and non-bank financials are recommended for mid-term investment [6][10]